期刊
TRENDS IN BIOCHEMICAL SCIENCES
卷 32, 期 10, 页码 450-456出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibs.2007.09.001
关键词
-
资金
- Biotechnology and Biological Sciences Research Council [BBS/B/13330] Funding Source: researchfish
Owing to its widespread activation in inflammation and cancer, a growing appreciation of the therapeutic potential of inhibitors of the phosphoinositide 3-kinase (PI3K) pathway has stimulated intense interest in compounds with suitable pharmacological profiles. These are primarily directed toward PI3K itself. However, as class I PI3Ks are also essential for a range of normal physiological processes, broad spectrum PI3K inhibition could be poorly tolerated. In recent years, patents describing a new generation of PI3K inhibitors have started to appear, with a particular focus on the development of compounds with enhanced isoform selectivity for use as anti-cancer and anti-inflammatory therapies. However, challenges remain for the efforts to pharmacologically target this enzyme family in a successful manner.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据